Abstract
Sitafloxacin is a fluoroquinolone antibacterial with in vitro activity against a broad range of Grampositive and -negative bacteria, including anaerobic bacteria, as well as against atypical pathogens. It is approved in Japan for use in a number of bacterial infections caused by sitafloxacin-susceptible strains of Staphylococcus spp., Streptococcus pneumoniae, other Streptococcus spp., Enterococcus spp., Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella spp., Enterobacter spp., Serratia spp., Proteus spp., Morganella morganii, Haemophilus influenzae, Pseudomonas aeruginosa, Legionella pneumophila, Peptostreptococcus spp., Prevotella spp., Porphyromonas spp., Fusobacterium spp., Chlamydia trachomatis, Chlamydophila pneumoniae and Mycoplasma pneumoniae.
In terms of clinical efficacy, oral sitafloxacin was noninferior to oral levofloxacin in the treatment of community-acquired pneumonia or an infectious exacerbation of chronic respiratory tract disease, non-inferior to oral tosufloxacin in the treatment of community-acquired pneumonia, and noninferior to oral levofloxacin in the treatment of complicated urinary tract infections, according to the results of randomized, double-blind, multicentre, noninferiority trials.
Noncomparative studies demonstrated the efficacy of oral sitafloxacin in otorhinolaryngological infections, urethritis in men, C. trachomatis- associated cervicitis in women and odontogenic infections.
Gastrointestinal disorders and laboratory abnormalities were the most commonly occurring adverse reactions in patients receiving oral sitafloxacin. Adverse reactions reported in sitafloxacin recipients in the active comparator trials were of mild to moderate severity.
Similar content being viewed by others
References
Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009 Sep; 64 Suppl. 1: i3–10
Ubukata K. Problems associated with high prevalence of multidrug-resistant bacteria in patients with community-acquired infections. J Infect Chemother 2003 Dec; 9(4): 285–91
Canton R, Morosini M, Enright MC, et al. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003 Dec; 52(6): 944–52
Yokota S, Sato K, Kuwahara O, et al. Fluoroquinoloneresistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob Agents Chemother 2002 Oct; 46(10): 3311–5
Slavin RG, Spector SL, Bernstein IL, et al. The diagnosis and management of sinusitis: a practice parameter update. J Allergy Clin Immunol 2005 Dec; 116 (6 Suppl.): S13–47
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007 Mar 1; 44 Suppl. 2: S27–72
Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011 Mar 1; 52(5): e103–20
Albertson TE, Chan AL. Antibiotic therapy in elderly patients with acute exacerbation of chronic bronchitis. Expert Rev Respir Med 2009 Oct; 3(5): 539–48
Yamaguchi K, Ohno A, Ishii Y, et al. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007 [in Japanese]. Jpn J Antibiot 2009 Aug; 62(4): 346–70
Daiichi Sankyo Co., Ltd. Gracevit® tablets 50 mg, fine granules 10%: prescribing information. Japan: 2009 Jun
Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62(1): 13–59
Okumura R, Hirata T, Onodera Y, et al. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quino-lone-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2008 Jul; 62(1): 98–104
Onodera Y, Uchida Y, Tanaka M, et al. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae. J Antimicrob Chemother 1999 Oct; 44(4): 533–6
Morrissey I, George JT. Inhibition of pneumococcal topoisomerases by sitafloxacin. Drugs 1999; 58 Suppl. 2: 354–5
Tanaka M, Onodera Y, Uchida Y, et al. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother 1997 Nov; 41(11): 2362–6
Hoshino K, Kitamura A, Morrissey I, et al. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 1994 Nov; 38(11): 2623–7
Amano A, Matsuzaki K, Kishi N, et al. In vitro activity of sitafloxacin against clinical isolates in 2009 [in Japanese]. Jpn J Antibiot 2010 Dec; 63(6): 411–30
Kanda H, Kurosaka Y, Fujikawa K, et al. In vitro and in vivo antibacterial activity of sitafloxacin [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 1–17
Yamamoto N, Fujita J, Shinzato T, et al. In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus. Int J Antimicrob Agents 2006 Feb; 27(2): 171–3
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute, 2008
Yokota S, Ohkoshi Y, Fujii N. Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates. Diagn Microbiol Infect Dis 2009 Sep; 65(1): 76–80
Giamarellou-Bourboulis EJ, Sambatakou H, Grecka P, et al. Sitafloxacin (DU-6859a) and trovafloxacin: post-antibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 1999 Aug; 34(4): 301–7
Mikamo H, Kawazoe K, Sato Y, et al. Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis. J Antimicrob Chemother 1998 Jan; 41(1): 131–3
Fukuda Y, Yanagihara K, Ohno H, et al. In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model. Antimicrob Agents Chemother 2006 Jan; 50(1): 121–5
Nakamura S, Yanagihara K, Araki N, et al. In vivo efficacy of sitafloxacin in a new murine model of non-typeable Haemophilus influenzae pneumonia by sterile intratracheal tube. Int J Antimicrob Agents 2009 Sep; 34(3): 210–4
Kurosaka Y, Ishida Y, Yamamura E, et al. Therapeutic efficacy of sitafloxacin against Pseudomonas aeruginosa in a rat model of urinary tract infection. Drugs 1999; 58 Suppl. 2: 412–4
Hong SG, Moland ES, Wickman PA, et al. In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in Gram-positive cocci. Antimicrob Agents Chemother 2007 Apr; 51(4): 1512–4
Touyama M, Higa F, Nakasone C, et al. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV. J Antimicrob Chemother 2006 Dec; 58(6): 1279–82
Saito A, Watanabe A, Aoki N, et al. Phase III double-blind comparative study of sitafloxacin versus tosufloxacin in patients with community-acquired pneumonia [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 49–62
Hori S, Kobayashi H, Saito A, et al. Clinical trials of sitafloxacin (DU-6859a): clinical safety profile [abstract no. L-489 plus poster]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)
Nakashima M, Uematsu T, Kosuge K, et al. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995 Jan; 39(1): 170–4
Saito A, Tanigawara Y, Watanabe A, et al. Open study of sitafloxacin in patients with respiratory tract infections: PK/PD study [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 63–80
Sasaki J, Hori S. Oral tissue distribution, efficacy, and safety of sitafloxacin in patients with dentistry and oral surgery infection [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 121–9
Baba S, Suzuki K, Yamanaka N, et al. Efficacy and safety of sitafloxacin in patients with otorhinolaryngological infections and its tissue distribution in the otorhinolaryngological field [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 110–20
O’Grady J, Briggs A, Atarashi S, et al. Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoro-quinolone antibiotic, in healthy male and female Caucasian subjects. Xenobiotica 2001 Nov; 31(11): 811–22
Payne GS, Collins DJ, Loynds P, et al. Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivo 19F magnetic resonance spectroscopy. Br J Clin Pharmacol 2005 Feb; 59(2): 244–8
Nakashima M. Pharmacokinetics of sitafloxacin (DU-6859a) in healthy volunteers [in Japanese]. Jpn J Chemother 2008; 56 Suppl. 1: 154–5
Nakashima M, Kawada Y. Pharmacokinetic profiles of sitafloxacin in patients with renal dysfunction [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 21–4
Sekino H. Pharmacokinetic profiles of sitafloxacin in elderly volunteers [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 18–20
Shiba K. Effect of ranitidine on sitafloxacin absorption [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 32–5
Shiba K. Effect of metal-ion on sitafloxacin absorption [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 25–31
Niki Y, Itokawa K, Okazaki O. Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies. Antimicrob Agents Chemother 1998 Jul; 42(7): 1751–5
MacGowan A, Rogers C, Bowker K. The use of in vitro pharmacodynamic models of infection to optimize fluoro-quinolone dosing regimens. J Antimicrob Chemother 2000 Aug; 46(2): 163–70
Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003 Apr; 22(4): 203–21
Kobayashi H, Watanabe A, Nakata K, et al. Double-blind comparative study of sitafloxacin versus levofloxacin in patients with respiratory tract infection [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 36–48
Kawada Y, Yasuda M, Tanaka K, et al. Dose-comparative study of sitafloxacin in complicated urinary tract infections [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 92–102
Kawada Y, Ishihara S, Matsui T, et al. Comparative study on sitafloxacin and levofloxacin in complicated urinary tract infections [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 81–91
Kawada Y, Matsumoto T, Onodera S, et al. Clinical study of sitafloxacin in male nongonococcal urethritis [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 130–8
Onodera S, Hori S. Clinical study of sitafloxacin in the treatment of male gonococcal urethritis [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 146–53
Matsuda S, Noguchi M, Yasuda J, et al. Clinical study of sitafloxacin in treatment of cervicitis with Chlamydia trachomatis [in Japanese]. Jpn J Chemother 2008 Apr; 56 Suppl. 1: 139–45
Dawe RS, Ibbotson SH, Sanderson JB, et al. A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br J Dermatol 2003 Dec; 149(6): 1232–41
Anderson DL. Sitafloxacin hydrate for bacterial infections. Drugs Today (Barc) 2008 Jul; 44(7): 489–501
Acknowledgements and Disclosures
The manuscript was reviewed by: S. Kohno, Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan; H. Lode, Institute for Clinical Pharmacology and Toxicology, Charitè Universitätsmedizin, Berlin, Germany; S. Yokota, Department of Microbiology, Sapporo Medical University School of Medicine, Sapporo, Japan.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Keating, G.M. Sitafloxacin. Drugs 71, 731–744 (2011). https://doi.org/10.2165/11207380-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11207380-000000000-00000